Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Abstract

Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. (Funded by Merck Sharp and Dohme; MOVe-OUT ClinicalTrials.gov number, NCT04575597.).

Keywords

Coronavirus disease 2019 (COVID-19)ProdrugSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus2019-20 coronavirus outbreakMedicineBetacoronavirusCoronavirus InfectionsVirologyIntensive care medicineInternal medicineDiseasePharmacologyInfectious disease (medical specialty)Outbreak

Affiliated Institutions

Related Publications

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel , Kay M Tomashek , Lori E. Dodd +37 more

Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory trac...

2020 New England Journal of Medicine 7559 citations

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech , Gary Albert , Iksung Cho +26 more

At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell res...

2020 New England Journal of Medicine 1219 citations

Publication Info

Year: 2021
Type: article
Volume: 386
Issue: 6
Pages: 509-520
Citations: 1826
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1826

OpenAlex

Cite This

APA Style

                            
                                
                                    Angélica Jayk Bernal, 
                                
                                    Monica Maria Gomes da Silva, 
                                
                                    Dany Badibanga Musungaie
                                
                                et al.
                            
                            (2021). 
                            Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. 
                            New England Journal of Medicine
                            , 386
                            (6)
                            , 509-520.
                            https://doi.org/10.1056/nejmoa2116044
                        

Identifiers

DOI: 10.1056/nejmoa2116044